Trial results

Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying

NCT01910194 on ClinicalTrials.gov · last registry update 2015-01-22

A small phase 2 — 39 participants, against a typical 114. The sponsor logged completion for October 2014. Primary outcome, as filed: AUCISEC(0-10min). lixisenatide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P2

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

Profil Institut für Stoffwechselforschung GmbH

Sponsor type

Industry

Enrollment

39

Started

2013-12

Primary completion

2014-10 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

AUCISEC(0-10min)

Conditions studied

Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.